

1 April, 2025

ASX Announcement

Share Sale by CEO & Executive Director

Austco Healthcare Limited (ACN 108 208 760) (ASX: AHC) (**Austco** or **the Company**) wishes to advise the market of the recent share trading by Clayton Astles, CEO and Executive Director.

Due to extraordinary personal circumstances, Mr Astles has sold 500,000 shares in the Company. The sale was undertaken to assist in funding medical expenses for an immediate family member in the United States.

Mr Astles remains committed to Austco Healthcare and continues to hold a shareholding in the company, reflecting his ongoing confidence in its long-term growth and strategy.

Given these challenging circumstances, the Board supports Mr Astles' sale of his shares, and its thoughts are with Mr Astles and his family during this difficult time.

Attached is the relevant ASX Appendix 3Y.

This announcement was approved by the Board of Austco Healthcare Limited.

For further information please contact:

Contact

Clayton Astles

CEO and Executive Director
Telephone AUS: +61 411 531 170
Telephone US: +1 416 565 7457
Email: clayton.astles@austco.com

Brendan Maher

Chief Financial Officer and Company Secretary
Telephone AUS: +61 439 369 551
Email: brendan.maher@austco.com

About Austco Healthcare Limited

Austco Healthcare Limited (Austco) is an ASX listed company based in Port Melbourne, Victoria and an international provider of healthcare communication and clinical workflow management solutions. Headquartered in Australia, the Company has subsidiaries in six countries and supports healthcare facilities through its global reseller network which includes growing markets in health, aged care and acute care. Austco Healthcare services markets include Australia, New Zealand, Canada, UK, USA, Asia and the Middle East. For further information please refer to the Company's website www.austcohealthcare.com.au.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AUSTCO HEALTHCARE LIMITED
ABN: 67 108 208 760

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Clayton Astles
Date of last notice	31 October 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	Between 25 March and 28 March 2025

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>Direct: 2,954,800 Ordinary Shares</p> <p>1,350,000 Unlisted options with an exercise price of \$0.215 expiring on 24 September 2025</p> <p>677,486 Unlisted Performance Rights expiring 30 September 2026</p> <p>821,739 Unlisted Performance Rights expiring 30 November 2027</p> <p>Indirect: 1,440,643 Ordinary Shares (held via HSBC Custody Nominees (Australia) Limited for the Clayton Astles RRSP account)</p> <p>91,804 Ordinary Shares (held via Clayton Astles ATF the Clayton Astles RRSP account)</p>
<p>Class</p>	<p>Ordinary Shares</p>
<p>Number acquired</p>	<p>-</p>
<p>Number disposed</p>	<p>500,000 Ordinary Shares</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>\$143,748.21 at an average price of \$0.2875 per share</p>
<p>No. of securities held after change</p>	<p>Direct: 2,454,800 Ordinary Shares</p> <p>1,350,000 Unlisted options with an exercise price of \$0.215 expiring on 24 September 2025</p> <p>677,486 Unlisted Performance Rights expiring 30 September 2026</p> <p>821,739 Unlisted Performance Rights expiring 30 November 2027</p> <p>Indirect: 1,440,643 Ordinary Shares (held via HSBC Custody Nominees (Australia) Limited for the Clayton Astles RRSP account)</p> <p>91,804 Ordinary Shares (held via Clayton Astles ATF the Clayton Astles RRSP account)</p>

+ See chapter 19 for defined terms.

For personal use only

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On market trades.
---	-------------------

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

For personal use only